alan knowles, managing director of cura financial services, said: “scottish widows are delivering on their word to customers by paying the majority of the claims they see.
.
eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
.
.
.
.